All 9 /Events 0 /In The News 7 /Press Releases 2

NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme

Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an…
22 February 2023/by Webadm

MJFF grant supports NRG Therapeutics’ work to validate mitochondrial drug target for Parkinson’s

Bioworld

Read more
22 February 2023/by Webadm

NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Gilles Ouvry Ph.D, appointed to newly created position of…
9 February 2023/by Webadm

Case Study: R&D grant funding

BIA, UK BioIndustry Association

Read more
27 January 2023/by Webadm

Parkinson’s disease drug hunters think outside the α-synuclein box

Nature Biotechnology

Read more
(behind paywall)
7 December 2022/by Webadm

NRG raises Series A funds for Parkinson’s and ALS therapy development

Pharmaceutical Technology

Read more
10 November 2022/by Webadm

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

Labiotech

Read more
10 November 2022/by Webadm

NRG announces £16m Series A for IND for Parkinson’s and ALS

PharmaPhorum

Read more
9 November 2022/by Webadm

Following the path to a new drug, together

Parkinson’s UK

Read more
9 November 2022/by Webadm

Novel Parkinson’s therapy protects mitochondrial function

Drug Discovery World Read more

NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases

First development candidate selected, NRG5051, with potential…

NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation

Business Weekly Read more

NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy

ALS News Today Read more

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND

Stevenage, UK, 5 August 2024 - NRG Therapeutics, Ltd., an innovative…

Case Study: Life Sciences – Future50

PwC Read more (pdf)

NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair

Stevenage, UK, 26 April 2023 - NRG Therapeutics, Ltd., an innovative…

NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Vad Lazari Ph.D., appointed to newly created position of…

9 neuroscience biotech companies you should know about

Labiotech Read more